immunoconjugates

Preferred Label : immunoconjugates;

MeSH definition : Combinations of diagnostic or therapeutic substances linked with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; or ANTIGENS. Often the diagnostic or therapeutic substance is a radionuclide. These conjugates are useful tools for specific targeting of DRUGS and RADIOISOTOPES in the CHEMOTHERAPY and RADIOIMMUNOTHERAPY of certain cancers.;

MeSH synonym : immunoconjugate;

MeSH hyponym : radioimmunoconjugates; Antibody Drug Conjugates; Conjugates, Antibody-Drug; Radioimmunoconjugate; Antibody-Drug Conjugate; Conjugate, Antibody-Drug; Antibody Drug Conjugate; Conjugate, Antibody Drug; Drug Conjugate, Antibody;

Wikipedia link : https://en.wikipedia.org/wiki/Immunoconjugates;

Is substance : O;

Details

Origin ID

D018796;

UMLS CUI

C0243020;

Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- analysis [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- drug effects [MeSH Qualifier]
- economics [MeSH Qualifier]
- genetics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- ultrastructure [MeSH Qualifier]
- urine [MeSH Qualifier]
Currated CISMeF NLP mapping
- Immunoconjugate [NCIt concept]
Indexing information
- OST7-(1-(4-(4-(2-maleimidoethoxy)succinamido)benzyl)ethylenediamine-N,N,N',N'-tetraacetic acid) [MeSH Supplementary Concept]
- PsL-EGFmAb-BSA4-(Gd-DTPA)n [MeSH Supplementary Concept]
- lead-203 DOTA-B72.3 [MeSH Supplementary Concept]
- technetium tc 99m-monoclonal antibody-170H.82 [MeSH Supplementary Concept]
Pharmacological action(s)
- immunologic factors [MeSH Descriptor]
Record concept(s)
- Antibody-Drug Conjugates [MeSH concept]
- immunoconjugates [MeSH concept]
- radioimmunoconjugates [MeSH concept]
Related MeSH Supplementary Concept(s)
- ABT-414 [MeSH Supplementary Concept]
- AGS67E [MeSH Supplementary Concept]
- AMG 595 [MeSH Supplementary Concept]
- ANG4043 [MeSH Supplementary Concept]
- ASP2408 [MeSH Supplementary Concept]
- ASP2409 [MeSH Supplementary Concept]
- BACH 250-rGel [MeSH Supplementary Concept]
- CMD 195 [MeSH Supplementary Concept]
- D2C7-(scdsFv)-PE38KDEL [MeSH Supplementary Concept]
- DMUC5754A [MeSH Supplementary Concept]
- ETI104 [MeSH Supplementary Concept]
- Erb-hcAb [MeSH Supplementary Concept]
- IMMU-110 [MeSH Supplementary Concept]
- LMB-100 [MeSH Supplementary Concept]
- MDX-1203 [MeSH Supplementary Concept]
- MLN2704 antibody [MeSH Supplementary Concept]
- MOC31PE immunotoxin [MeSH Supplementary Concept]
- N901 MoAb-blocked ricin conjugate [MeSH Supplementary Concept]
- OST7-(1-(4-(4-(2-maleimidoethoxy)succinamido)benzyl)ethylenediamine-N,N,N',N'-tetraacetic acid) [MeSH Supplementary Concept]
- OX7-saporin [MeSH Supplementary Concept]
- RFT5-SMPT-dgA immunotoxin [MeSH Supplementary Concept]
- SGN-LIV1A [MeSH Supplementary Concept]
- TXU-pokeweed antiviral protein, phytolacca [MeSH Supplementary Concept]
- anetumab ravtansine [MeSH Supplementary Concept]
- anti-B4 blocked ricin immunoconjugate [MeSH Supplementary Concept]
- aprutumab ixadotin [MeSH Supplementary Concept]
- chFRP5-ZZ-PE38 [MeSH Supplementary Concept]
- copper-64-DOTA-NR-LU-10 [MeSH Supplementary Concept]
- cpIL-4(13D)-PE38KDEL immunotoxin [MeSH Supplementary Concept]
- gancotamab [MeSH Supplementary Concept]
- genistein-17.1A immunoconjugate [MeSH Supplementary Concept]
- glembatumumab vedotin [MeSH Supplementary Concept]
- hI-con1 [MeSH Supplementary Concept]
- hdsFv25, human [MeSH Supplementary Concept]
- huB3F6-SPDB-DM4 immunoconjugate [MeSH Supplementary Concept]
- indatuximab ravtansine [MeSH Supplementary Concept]
- mirvetuximab soravtansine [MeSH Supplementary Concept]
- naptumomab estafenatox [MeSH Supplementary Concept]
- oncolysin B [MeSH Supplementary Concept]
- pinatuzumab vedotin [MeSH Supplementary Concept]
- polatuzumab vedotin [MeSH Supplementary Concept]
- rovalpituzumab tesirine [MeSH Supplementary Concept]
- sacituzumab govitecan [MeSH Supplementary Concept]
- sirtratumab vedotin [MeSH Supplementary Concept]
- trastuzumab deruxtecan [MeSH Supplementary Concept]
- trastuzumab-vc-MMAE [MeSH Supplementary Concept]
See also
- molecular targeted therapy [MeSH Descriptor]
Semantic type(s)
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
Substance(s)
- BAY 2315497 [MeSH Supplementary Concept]
- CX-2029 [MeSH Supplementary Concept]
- LY3076226 [MeSH Supplementary Concept]
- MEDI3726 [MeSH Supplementary Concept]
- MEDI4276 [MeSH Supplementary Concept]
- cofetuzumab pelidotin [MeSH Supplementary Concept]
- disitamab vedotin [MeSH Supplementary Concept]
UMLS correspondences (same concept)
- Immunoconjugate [NCIt concept]
Validated automatic mappings to BTNT
- Radioimmunoconjugate [NCIt concept]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients